Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Silence

<< Previous

Bullboard Posts

Next >>

Comment by Cb27743on Dec 06, 2022 6:09pm

145 Views

Post# 35154714

RE:RE:RE:RE:RE:Silence

I hear your frustration,

We are still waiting for reviewed data from their completed 2021 P2 trial which usually takes 6 from what I heard on another market platform. The last update we recieved from Management regarding the P2 trial was August 2021. Unless there is other material updates we are not aware of? We are almost into 2023 and still ghosted. Is this still being reviewed? was the data positive?

Insiders have bought more earlier this year and smaller amounts in spring/fall, which is a good sign regarding the company status IMO.

And great question, their cash won't last forever, when do they plan on another raise? What is their plan?

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta